PerkinElmer Posts 6 Percent Revenue Growth | GenomeWeb

NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its fourth-quarter revenues rose 6 percent, while its bottom line was hit by a large asset impairments charge.

The Waltham, Mass.-based analytical tools firm brought in total revenues of $572.9 million for the three months ended Dec. 30, 2012, compared to $539.3 million for the fourth quarter of 2011, and up 3 percent on an organic basis. It beat Wall Street's estimate of $578.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.